Navigation Links
Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
Date:9/5/2007

U.S. Biogeneric Agents to Reach $2 Billion in Sales by 2016, According to a

New Report from Decision Resources

WALTHAM, Mass., Sept. 5 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen, the leading manufacturer of biologic agents with biologic sales of more than $14 billion in 2006, and Genentech, the second leading biologics manufacturer with biologic sales of more than $9 billion in 2006, are bracing themselves for heavy pressure from biogeneric manufacturers. According to the new special report entitled Biogenerics 2007- 2016: Physician and Payer Acceptance Fuels Brand Erosion, Amgen products such as Enbrel, Epogen and Neupogen will be eroded by biogeneric sales in both the United States and Europe. In fact, on August 31, 2007, European regulators approved Sandoz's biogeneric epoetin alfa for patients with renal anemia and those receiving chemotherapy. Genentech products such as Rituxan/MabThera and Herceptin represent windfall opportunities for biogeneric hopefuls.

The report also reveals that, with the launch of biogeneric TNF-alpha inhibitors in 2012, the U.S. biogeneric market will expand substantially through 2016 and reach a total of more than $2 billion in annual sales.

"This growth in the U.S. biogeneric market will be driven by biogeneric TNF-alpha inhibitors for rheumatoid arthritis, which we project will generate $700 million in sales by 2016, and will be supported by biogeneric versions of interferon-betas for multiple sclerosis, Herceptin for breast cancer, and ESPs for chemotherapy-induced anemia, each of which will post more than $250 million in 2016 U.S. sales," said Andrew Merseth, analyst at Decision Resources.

About Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion

Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion covers 13 key biologic brands used in eight indications and includes more primary research than any other report produced by Decision Resources. It includes surveys of 317 specialists from the United States, France, and Germany as well as 40 U.S. HMO pharmacy directors. The report includes a 10- year annualized forecast for the 13 key brands and for their biogeneric competition, and provides a framework for forecasting other biogenerics.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Genentechs Winning Streak
2. TeraMedica embraces open source project
3. Center for Technology Transfer embraces "Cleantech"
4. Wisconsin Film Festival embraces new online ticket ordering system
5. Wisconsin Historical Society Embraces New Web Site Technology
6. Chippewa Valley Embraces Nanotechnology
7. Wisconsin early-stage companies must position themselves to get capital
8. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
9. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
10. Cellular Dynamics hits market with UW research heavyweights
11. Governors Growth Council hopes to go light on paperwork and heavy on ideas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... manufacturing company, today announced several positive developments that position the Company for the ... result of the transaction, Craig F. Kinghorn has been appointed Chairman of the ...
(Date:5/25/2016)... ... 2016 , ... Founder of the Fitzmaurice Hand Institute in ... of the hand by the National Board of Physicians and Surgeons, as of ... in his pursuit of providing the most comprehensive, effective treatment for his patients, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. ... the company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar ... FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is ...
(Date:5/23/2016)... ... ... need for blood donations in South Texas and across the nation is growing. , But ... blood donations are on the decline. In fact, donations across the country are at their ... Texas in the last four years alone. , There is no substitute for blood. , ...
Breaking Biology Technology:
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/15/2016)... 15, 2016 Yissum Research Development Company ... company of the Hebrew University, announced today the formation ... technology of various human biological indicators. Neteera Technologies has ... from private investors. ... detection of electromagnetic emissions from sweat ducts, enables reliable ...
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
Breaking Biology News(10 mins):